343 related articles for article (PubMed ID: 9553686)
1. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1996 Aug; 46(8):766-73. PubMed ID: 9125276
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of estradiol and of estrone during application of three strengths of an estradiol transdermal patch with active matrix.
Setnikar I; Rovati LC; Thebault JJ; Guillaume M; Mignot A; Renoux A; Gualano V
Arzneimittelforschung; 1997 Jul; 47(7):859-65. PubMed ID: 9272245
[TBL] [Abstract][Full Text] [Related]
4. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch.
Setnikar I; Rovati LC; Santoro A; Guillaume M; Mignot A; Renoux A; Gualano V
Arzneimittelforschung; 1999 Aug; 49(8):708-15. PubMed ID: 10483519
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of estradiol from two transdermal patches.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1996 Mar; 46(3):307-10. PubMed ID: 8901155
[TBL] [Abstract][Full Text] [Related]
6. Plasma profiles of transdermal 17 beta-estradiol delivered by two different matrix patches. A four-way cross-over study in postmenopausal women.
Rohr UD; Ehrly AM; Kuhl H
Arzneimittelforschung; 1997 Jun; 47(6):761-7. PubMed ID: 9239456
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a 7 day 17 beta-estradiol transdermal delivery system: pharmacokinetics in healthy postmenopausal women.
Boyd RA; Zegarac EA; Eldon MA; Sedman AJ; Forgue ST
Biopharm Drug Dispos; 1996 Aug; 17(6):459-70. PubMed ID: 8866037
[TBL] [Abstract][Full Text] [Related]
8. [Bioavailability of 17 beta-estradiol after transdermal administration--dependence on the patch system].
Schmolling J; Kusche J; van der Ven H; Schander K
Zentralbl Gynakol; 1998; 120(3):121-5. PubMed ID: 9556902
[TBL] [Abstract][Full Text] [Related]
9. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara.
Buch A; Shen L; Kelly S; Sahota R; Brezovic C; Bixler C; Powell J
Menopause; 1998; 5(2):107-12. PubMed ID: 9689205
[TBL] [Abstract][Full Text] [Related]
10. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
[TBL] [Abstract][Full Text] [Related]
11. Steady-state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women.
Morton TL; Gattermeir DJ; Petersen CA; Day WW; Schumacher RJ
J Clin Pharmacol; 2009 Sep; 49(9):1037-46. PubMed ID: 19628730
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol.
Scott RT; Ross B; Anderson C; Archer DF
Obstet Gynecol; 1991 May; 77(5):758-64. PubMed ID: 2014092
[TBL] [Abstract][Full Text] [Related]
13. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
Rohr UD; Nauert C; Stehle B
Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability and pharmacokinetic profile of glyceryl trinitrate and of glyceryl dinitrates during application of a new glyceryl trinitrate transdermal patch.
Santoro A; Rovati LC; Setnikar I; Caplain H; Gualano V
Arzneimittelforschung; 2000 Sep; 50(9):779-85. PubMed ID: 11050693
[TBL] [Abstract][Full Text] [Related]
15. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17 beta-estradiol.
Kuhnz W; Gansau C; Mahler M
Arzneimittelforschung; 1993 Sep; 43(9):966-73. PubMed ID: 8240460
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of orally administered estradiol valerate. Results of a single-dose cross-over bioequivalence study in postmenopausal women.
Zimmermann H; Koytchev R; Mayer O; Börner A; Mellinger U; Breitbarth H
Arzneimittelforschung; 1998 Sep; 48(9):941-7. PubMed ID: 9793623
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of 17beta-estradiol and estrone after multiple-dose administration of percutaneous estradiol gel in symptomatic menopausal women.
Brennan JJ; Lu Z; Whitman M; Stafiniak P; van der Hoop RG
Ther Drug Monit; 2001 Apr; 23(2):134-8. PubMed ID: 11294513
[TBL] [Abstract][Full Text] [Related]
19. Half-life of estradiol in postmenopausal women.
Ginsburg ES; Gao X; Shea BF; Barbieri RL
Gynecol Obstet Invest; 1998; 45(1):45-8. PubMed ID: 9473164
[TBL] [Abstract][Full Text] [Related]
20. Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol.
Price TM; Blauer KL; Hansen M; Stanczyk F; Lobo R; Bates GW
Obstet Gynecol; 1997 Mar; 89(3):340-5. PubMed ID: 9052581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]